153.23MMarket Cap-1875P/E (TTM)
5.795High5.420Low250.16KVolume5.750Open5.710Pre Close1.39MTurnover1.08%Turnover RatioLossP/E (Static)27.78MShares7.99052wk High9.71P/B127.91MFloat Cap2.25052wk Low--Dividend TTM23.19MShs Float7069.999Historical High--Div YieldTTM6.57%Amplitude-9223372036.855Historical Low5.567Avg Price1Lot Size
Delcath Systems Stock Forum
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...
Delcath Systems Receives Permanent J-Code For HEPZATO
Delcath Systems Launches Commercial Treatment Utilizing HEPZATO KIT For Treatment Of Metastatic Uveal Melanoma
•Partnered with seven clinical treatment sites to ...
No comment yet